Neuren Pharmaceuticals Reports Record Q2 2026 DAYBUE Sales

Neuren Pharmaceuticals (ASX: NEU) announced record second‑quarter 2026 DAYBUE net sales of US$125 million, up 30% year‑over‑year and 24% quarter‑over‑quarter, the highest level since the drug’s launch. The company raised its full‑year 2026 royalty‑income forecast to US$53‑56 million and increased its net‑sales guidance to US$480‑510 million. CEO Jon Pilcher credited strong volume growth, especially the new DAYBUE STIX powder formulation now used by 40% of U.S. patients, and noted a favourable CHMP opinion that should enable a German launch later in the year.

ClearPoint Neuro (NASDAQ: CLPT) reported Q2 2026 revenue of $10.9 million, an 18% increase from the prior year, driven by navigation‑and‑therapy product sales and the rollout of its 3.0 operating‑room navigation software. The firm lifted its full‑year 2026 revenue outlook to $48‑52 million while shifting investment toward clinical capacity and partner‑led trials. Gross margin improved to 62%, and cash balances fell to $29.4 million after a period of operational cash burn.